PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance

被引：14
作者：
Jia, Xiaoming [1 ]
Al Rifai, Mahmoud [1 ]
Saeed, Anum [2 ]
Ballantyne, Christie M. [1 ]
Virani, Salim S. [1 ,3 ]
机构：
[1] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[2] Univ Pittsburgh, Dept Med, Med Ctr, Pittsburgh, PA USA
[3] Michael E DeBakey VA Med Ctr, Dept Med, Houston, TX 77030 USA
来源：
VASCULAR HEALTH AND RISK MANAGEMENT | 2022年 / 18卷
关键词：
PCSK9; inhibitor; CVD prevention; lipids; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; PERIPHERAL ARTERY-DISEASE; 9; MONOCLONAL-ANTIBODY; COST-EFFECTIVENESS; DOUBLE-BLIND; ALIROCUMAB TREATMENT; LOWERS CHOLESTEROL; LDL CHOLESTEROL; REDUCING LIPIDS; AMG; 145;
D O I：
10.2147/VHRM.S275739
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholesterol (LDL-C) and impact on cardiovascular outcomes. Since the approval of commercial use for PCSK9 inhibitors in 2015, we have also gained significant experience in the use of these therapeutics in the real-world setting. In this article, we review current guideline recommendations, clinical trial evidence on efficacy and safety as well as data on cost-effectiveness, prescription and adherence. We focus primarily on the monoclonal antibody class of PCSK9 inhibitors in this review while also touching on other types of therapeutics that are under development.
引用
收藏
页码：555 / 566
页数：12
相关论文
共 50 条
[31]   Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia [J].
Whayne, Thomas F., Jr. .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2016, 16 (02) :83-92
[32]   PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility [J].
Raal, Frederick J. ;
Chilton, Robert ;
Ranjith, Naresh ;
Rambiritch, Virendra ;
Leisegang, Rory F. ;
Ebrahim, Iftikhar O. ;
van Tonder, Alet ;
Shunmoogam, Nelusha ;
Bouharati, Celia ;
Musa, Moji G. ;
Karamchand, Sumanth ;
Naidoo, Poobalan ;
Blom, Dirk J. .
ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2020, 20 (06) :840-854
[33]   PCSK9 inhibitors. Recommendations for patient selection [J].
Laufs, U. ;
Custodis, F. ;
Werner, C. .
HERZ, 2016, 41 (04) :296-306
[34]   Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes [J].
Myers, Kelly D. ;
Farboodi, Niloofar ;
Mwamburi, Mkaya ;
Howard, William ;
Staszak, David ;
Gidding, Samuel ;
Baum, Seth J. ;
Wilemon, Katherine ;
Rader, Daniel J. .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2019, 12 (08)
[35]   Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials [J].
Casula, Manuela ;
Olmastroni, Elena ;
Boccalari, Mezio T. ;
Tragni, Elena ;
Pirillo, Angela ;
Catapano, Alberico L. .
PHARMACOLOGICAL RESEARCH, 2019, 143 :143-150
[36]   Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors [J].
Pecin, Ivan ;
Hartgers, Merel L. ;
Hovingh, G. Kees ;
Dent, Ricardo ;
Reiner, Zeljko .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2017, 24 (13) :1383-1401
[37]   Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes [J].
Liberale, Luca ;
Montecucco, Fabrizio ;
Camici, Giovanni G. ;
Dallegri, Franco ;
Vecchie, Alessandra ;
Carbone, Federico ;
Bonaventura, Aldo .
CURRENT MEDICINAL CHEMISTRY, 2017, 24 (14) :1403-1416
[38]   Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy [J].
Krittanawong, Chayakrit ;
Khawaja, Muzamil ;
Rosenson, Robert S. ;
Amos, Christopher, I ;
Nambi, Vijay ;
Lavie, Carl J. ;
Virani, Salim S. .
CURRENT PROBLEMS IN CARDIOLOGY, 2022, 47 (07)
[39]   Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors [J].
Shahreyar, Muhammed ;
Salem, Salem A. ;
Nayyar, Mannu ;
George, Lekha K. ;
Garg, Nadish ;
Koshy, Santhosh K. G. .
JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2018, 31 (04) :628-634
[40]   PCSK9 as a therapeutic target for cardiovascular disease [J].
Zhang, Pei-Ying .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (03) :810-814
12345